N-terminal pro-Brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case control study

IntroductionPulmonary arterial hypertension is a major cause of mortality in systemic sclerosis. N-terminal pro-brain natriuretic peptide (NT-proBNP) has emerged as a candidate biomarker that may enable the early detection of systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH).

The objective of our study was to incorporate NT-proBNP into a screening algorithm for SSc-PAH that could potentially replace transthoracic echocardiography (TTE) as a more convenient and less costly 'first tier'test.

Methods: NT-proBNP levels were measured in patients from 4 clinical groups: a group with right heart catheter (RHC) diagnosed SSc-PAH prior to commencement of therapy for PAH; a group at high risk of SSc-PAH based on TTE; a group with interstitial lung disease; and systemic sclerosis (SSc) controls with no cardiopulmonary complications. NT-proBNP levels were compared using ANOVA and correlated with other clinical variables using simple and multiple linear regression.

ROC curve analyses were performed to determine the optimal cut-point for NT-proBNP and other clinical variables in prediction of PAH.

Results: NT-proBNP was highest in the PAH group compared to other groups (p<0.0001), and higher in the risk group compared to controls (p<0.0001). NT-proBNP was positively correlated with systolic pulmonary artery pressure (PAP) on TTE (p<0.0001), and mean PAP (p=0.013), pulmonary vascular resistance (p=0.005) and mean right atrial pressure (p=0.006) on RHC.

A composite model wherein patients screened positive if NT-proBNP [greater than or equal to] 209.8pg/ml, and/or DLCOcorr<70.3% with FVC/DLCOcorr [greater than or equal to] 1.82, had a sensitivity of 100% and specificity of 77.8% for SSc-PAH.

Conclusion: We have proposed a screening algorithm for SSc-PAH, incorporating NT-proBNP level and PFTs. This model has high sensitivity and specificity for SSc-PAH and if positive, should lead to TTE and confirmatory testing for PAH.

This screening algorithm needs to be validated prospectively.

Author: Vivek ThakkarWendy M StevensDavid PriorOwen A MooreJillian ByronDanny LiewKaren PattersonPravin HissariaJanet RoddyJane ZochlingJoanne SahharPeter NashKathleen TymmsDavid CelermajerEli GabbayPeter YoussefSusanna M ProudmanMandana Nikpour

Published on: 2012-06-12

Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.


Custom Search


© 2015 7thSpace Interactive
All Rights Reserved - About | Disclaimer | Helpdesk